pH-Responsive Single Walled Carbon Nanotube Dispersion for Target Specific Release of Doxorubicin to Cancer Cells

Figure S1. a) AFM and b) TEM image of SWCNT-1 nanohybrid.

Figure S2. The histogram for average bundle diameter of dispersed SWCNTs.

Figure S3. The histogram for average length of the nanotubes of dispersed SWCNTs.

Figure S4. % Cell viability of CHO, NIH3T3, HepG2 and Hela cells incubated with SWCNT-1 hybrid after 24 h of incubation.

Figure S5. % Cell viability of CHO, NIH3T3, HepG2 and Hela cells incubated with SWCNT-2 hybrid after 24 h of incubation.

Figure S6. Time dependent emission spectra of SWCNT-2-DOX.

Figure S7. Stability of SWCNT-DOX at pH 8 and at lower pH.

Figure S8. pH-dependent revival of intrinsic a) fluorescence b) UV absorbance peak of doxorubicin in SWCNT-1-DOX.

Figure S9. pH-dependent a) fluorescence b) UV absorbance peak of doxorubicin.

Figure S10. pH-dependent release profile of doxorubicin and its quantification.

Figure S11. IC₅₀ values of the doxorubicin for CHO, NIH3T3, Hela and HepG2 cells

Figure S12. Bright field and fluorescence microscopic images of cells incubated with BSA-FITC loaded SWCNT-2 for 6 h in a,b) CHO cells c,d) Hela cells.

Figure S13. Bright field and fluorescence microscopic images of cells incubated with BSA-FITC for 6 h in a,b) CHO cells c,d) Hela cells.

Figure S14. % Cell viability of CHO and Hela cells incubated with amphiphile+DOX hybrid after 12 h of incubation.

Figure S15. Bright field and fluorescence microscopic images of cells incubated with DOX loaded SWCNT-1 for 6 h in a,b) CHO cells c,d) Hela cells e,f) HepG2 cells.

Scheme S1. Synthetic scheme for 1-4.